S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market

Pyxis Oncology (PYXS) Stock Forecast & Price Target

$4.16
-0.37 (-8.17%)
(As of 04/19/2024 ET)

Pyxis Oncology Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$8.50
104.33% Upside
High Forecast$12.00
Average Forecast$8.50
Low Forecast$7.00
TypeCurrent Forecast
4/22/23 to 4/21/24
1 Month Ago
3/23/23 to 3/22/24
3 Months Ago
1/22/23 to 1/22/24
1 Year Ago
4/22/22 to 4/22/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.50$9.60$8.33$14.00
Predicted Upside104.33% Upside166.22% Upside311.52% Upside536.36% Upside
Get Pyxis Oncology Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.

PYXS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PYXS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pyxis Oncology Stock vs. The Competition

TypePyxis OncologyMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside104.33% Upside1,020.62% Upside11.93% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/10/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Ramakanth
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00+30.84%
3/22/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$7.00+51.84%
2/9/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$8.00+115.63%
1/23/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. La. Rosa
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/23/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$12.00+370.59%
11/8/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
4/26/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Slutsky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:46 AM ET.

PYXS Price Target - Frequently Asked Questions

What is Pyxis Oncology's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Pyxis Oncology stock is Buy based on the current 7 buy ratings for PYXS. The average twelve-month price prediction for Pyxis Oncology is $8.50 with a high price target of $12.00 and a low price target of $7.00. Learn more on PYXS's analyst rating history.

Do Wall Street analysts like Pyxis Oncology more than its competitors?

Analysts like Pyxis Oncology more than other Medical companies. The consensus rating for Pyxis Oncology is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how PYXS compares to other companies.

Does Pyxis Oncology's stock price have much upside?

According to analysts, Pyxis Oncology's stock has a predicted upside of 109.62% based on their 12-month stock forecasts.

What analysts cover Pyxis Oncology?

Pyxis Oncology has been rated by BTIG Research, HC Wainwright, Leerink Partnrs, Royal Bank of Canada, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:PYXS) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners